Dashboard
Manage Tickers

IRON


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

raymond-james-maintains-strong-buy-on-disc-medicine-raises-price-target-to-108
Raymond James Maintains Strong Buy on Disc...
10/17/2025 16:20:18

Raymond James analyst Michael Freeman maintains Disc Medicine (NASDAQ:IRON) with a Strong Buy and raises the price target fr...

gold-falls-1-slb-posts-better-than-expected-q3-earnings
Gold Falls 1%; SLB Posts Better-Than-Expec...
10/17/2025 16:17:56

revolution-medicines-disc-medicine-american-express-and-other-big-stocks-moving-higher-on-friday
Revolution Medicines, Disc Medicine, Ameri...
10/17/2025 16:02:18

cantor-fitzgerald-maintains-overweight-on-disc-medicine-raises-price-target-to-153
Cantor Fitzgerald Maintains Overweight on ...
10/17/2025 14:20:15

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target...

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times
FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

disc-medicine-to-present-clinical-data-from-its-phase-1b-trial-of-disc-0974-at-upcoming-2025-american-society-of-nephrology-kidney-week-in-houston-texas-from-november-69-2025
Disc Medicine To Present Clinical Data Fro...
10/17/2025 13:04:09

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commer...

wedbush-maintains-outperform-on-disc-medicine-raises-price-target-to-110
Wedbush Maintains Outperform on Disc Medic...
10/17/2025 12:31:35

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from ...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/17/2025 12:13:10

disc-medicine-receives-fda-commissioners-national-priority-voucher-for-bitopertin-in-erythropoietic-protoporphyria-disc-is-seeking-accelerated-approval-of-bitopertin-for-patients-aged-12-years-and-older-with-epp-the-cnpv-program-is-designed-to-reduce-the-drug-application-review-process-to-1-2-months
Disc Medicine Receives FDA Commissioner's ...
10/16/2025 21:39:03

WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical compa...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/16/2025 21:06:04

disc-medicine-submits-new-drug-application-to-fda-for-accelerated-approval-of-bitopertin-for-patients-with-erythropoietic-protoporphyria
Disc Medicine Submits New Drug Application...
09/30/2025 12:34:51

morgan-stanley-maintains-overweight-on-disc-medicine-raises-price-target-to-90
Morgan Stanley Maintains Overweight on Dis...
08/18/2025 13:19:54

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from ...

disc-medicine-q2-eps-158-misses-113-estimate
Disc Medicine Q2 EPS $(1.58) Misses $(1.13...
08/07/2025 12:36:14

Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.1...

truist-securities-initiates-coverage-on-disc-medicine-with-buy-rating-announces-price-target-of-86
Truist Securities Initiates Coverage On Di...
07/21/2025 12:10:42

Truist Securities analyst Danielle Brill initiates coverage on Disc Medicine (NASDAQ:IRON) with a Buy rating and announces P...

disc-medicine-received-feedback-from-fda-from-its-pre-nda-meeting-for-nda-submission-for-bitopertin-in-epp
Disc Medicine Received Feedback From FDA F...
07/21/2025 12:08:17

morgan-stanley-assumes-disc-medicine-at-overweight-announces-price-target-of-85
Morgan Stanley Assumes Disc Medicine at Ov...
07/03/2025 17:41:57

Morgan Stanley analyst Sean Laaman assumes Disc Medicine (NASDAQ:IRON) with a Overweight rating and announces Price Target o...

hc-wainwright--co-reiterates-buy-on-disc-medicine-maintains-118-price-target
HC Wainwright & Co. Reiterates Buy on Disc...
07/03/2025 11:16:47

HC Wainwright & Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:IRON) with a Buy and maintains $118 price target.

hc-wainwright--co-reiterates-buy-on-disc-medicine-maintains-118-price-target
HC Wainwright & Co. Reiterates Buy on Disc...
06/17/2025 10:56:11

HC Wainwright & Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:IRON) with a Buy and maintains $118 price target.

disc-medicine-highlights-new-clinical-data-on-three-drug-candidates-for-rare-blood-and-iron-disorders-plans-fda-filing-for-bitopertin-after-epp-study
Disc Medicine Highlights New Clinical Data...
06/12/2025 11:36:14

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commer...

raymond-james-reinstates-strong-buy-on-disc-medicine-announces-89-price-target
Raymond James Reinstates Strong Buy on Dis...
06/11/2025 16:29:00

Raymond James analyst Michael Freeman reinstates Disc Medicine (NASDAQ:IRON) with a Strong Buy and announces $89 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION